Topical Compounded Pain Creams And Pain Perception (TOPCAPP) (TOPCAPP)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Perceived pain changes [ Time Frame: 12 Week Study [Baseline, 4,8, and 12 week evaluation] ]
Minimal sample size of 60 persons(maximum n=150)with a diagnosis of chronic pain (n=30 neuropathic and n=30 nociceptive primary pain-type)to determine predictors of a 30% or greater reduction of pain scores evaluated by logistic regression analyses utilizing the Brief Pain Index scores.
Secondary Outcome Measures :
Quality of Life [ Time Frame: 12 Weeks [Baseline,4,8, and 12 week evaluation] ]
To evaluate the change in quality of life using the EuroQol-5D-3L survey.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 65 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Participants with neuropathic or nociceptive chronic pain who are between 18 and 65 years of age prescribed a combination compounded topical analgesic.
Participants must be diagnosed with an ICD9 code indicative of chronic pain.
Participants must be starting a new regimen of topical therapy with multiple compounded agents.
Participants must be expecting to receive therapy for at least 12 weeks.
Participants must be between 18 and 65 years of age.
Participants must be able to provide sound written and verbal informed consent.
Participants must not have prior hypersensitivity or adverse events to any of the components in the customized prescription.
Participants must not be pregnant or breastfeeding women.
Participants must not have a diagnosis of cancer within the past 5 years.